According to a May 31 release from Hackensack Meridian Health, experts from northern New Jersey, New York City, and California are teaming forces to investigate and develop antiviral medicines for SARS-CoV-2, its variations, other coronaviruses and pandemic viruses, as well as future viral threats.
The new Metropolitan Antiviral Drug Accelerator, or MAVDA, will be supported by a three-year, $65,141,731 grant from the National Institutes of Health and the Antiviral Drug Discovery Centers for Pathogens of Pandemic Concern program of the National Institute of Allergy and Infectious Diseases.
The collaboration will include academic and pharmaceutical professionals from the Hackensack Meridian Center for Discovery and Innovation (CDI) in Nutley, Rutgers University, and Merck in Rahway, all from the Garden State.
Rockefeller University, Columbia University, Memorial Sloan-Kettering Cancer Center, and the Tri-Institutional Therapeutics Discovery Institute will be among the New York donors. Aligos Therapeutics, a California-based company, will also take part.